The company’s lead drug candidate, linzagolix (branded as Yselty), is an orally administered GnRH receptor antagonist that has completed two Phase 3 studies, PRIMROSE 1 in the US and PRIMROSE 2 in both the US and Europe. The clinical trials enrolled 574 and 535 patients, respectively, and used doses of 100mg or 200mg to treat heavy menstrual bleeding associated...
The whole market is up and down, but OBSV is one of few in the green. The Daily chart shows a bullish pattern and we are gearing up to break out. MACD is closing red and the RSI is heading up. The past 2 days has seen an increase in volume. Putting a 7.50 price target using the flag pole method.
TA algos looking good for this one.
- Established support.
- Increased volume + solid move up.
What to expect: Small consolidation. (retest) - then move up.
Target: $7 mark
Don't take my word for it. Program is the one calling it, not me.
Don't forget, market is way overheated these days. Pullback coming sooner than later.
we gonna see this run up at least 2 more dollars. analysts have price targets in the $20s and I'm excited. gonna be patient and play an option cus i'm a psychopath. good luck happy trading
correction could be seen to the high three's
I hope you're having a Good Friday night. I came across this gem yesterday and I have to give it a shout out. ObsEva is a unique company, and has lots of potential. They have three drugs currently in pipelines. Its recently broken out and is channeling upward and moving very healthily. I have a price target of $10+. With a long term hold.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual...
Fairly new biotech focusing on women reproductive systems.
The is not a huge amount of volume on it daily and the price movement is fairly slow and consistent.
I circled the "dent" Covid put into the stock... clearly not much at all showing this beats to its own drum.
From a TA standpoint, i would really like to see this gap get filled back to at least...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based based. That being said, at the current price for OBSV I think it can still find support and retrace to a $6.48 price threshold. This means for a short term stock, if I may right, there may be potential for a decent profit turnover a short period of...
ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.